--- title: "Chinese Drugmaker Huahai Rises After Signing USD340 Million Deal With Spain’s Almirall" type: "News" locale: "en" url: "https://longbridge.com/en/news/281025500.md" description: "Huahai Pharmaceutical's shares rose 2.3% to CNY16.18 after announcing a USD340 million licensing deal with Spain's Almirall for a new monoclonal antibody targeting skin diseases. The agreement includes upfront and milestone payments, with royalties on sales. Huahai retains rights in China while Almirall holds rights outside the country. This deal reflects the growing trend of cross-border collaborations among Chinese drugmakers, with outbound licensing deals for innovative drugs reaching USD60 billion in Q1." datetime: "2026-03-30T13:02:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281025500.md) - [en](https://longbridge.com/en/news/281025500.md) - [zh-HK](https://longbridge.com/zh-HK/news/281025500.md) --- # Chinese Drugmaker Huahai Rises After Signing USD340 Million Deal With Spain’s Almirall (Yicai) March 30 -- Huahai Pharmaceutical’s shares gained after the Chinese drugmaker said a deal with Spanish dermatology specialist Almirall could bring in royalty payments of USD340 million. Huahai Pharma \[SHA: 600521\] closed 2.3 percent higher at CNY16.18 (CNY2.34) per share in Shanghai today, after earlier climbing by as much as 3.4 percent. Shanghai Huaota Biopharmaceutical, a unit of Taizhou-based Huahai, has reached a global research and licensing agreement with Almirall to develop a new-targeted monoclonal antibody candidate for skin diseases and other potential uses, it announced late on March 27. Under the deal, Almirall will pay Huaota as much as USD340 million in licensing fees tied to drug development, regulatory approval, and commercial sales, including an upfront payment, as well as milestone payments linked to clinical trials, new drug registration, and commercialization. Huaota keeps the China rights, while Almirall gets the rights outside of the country. After the new drug reaches the market, both parties will also receive royalties from each other’s respective sales, according to an agreed-upon percentage. Chinese drugmakers are attracting more cross-border deals as their capabilities strengthen. In the first quarter, outbound licensing deals for China’s innovative drugs topped USD60 billion, already close to half of last year’s total, an official with the National Medical Products Administration said at a forum last week. Barcelona-based Almirall is a global dermatological drugmaker whose products are sold in more than 100 countries, Huahai said. Huahai is primarily a generics maker, but through Huaota it has been building a pipeline in biologics and novel treatments, with programs spanning oncology, autoimmune disease, and ophthalmology. Huaota is one of the few Chinese drugmakers with full-chain research abilities, from early development to pilot production. Editor: Tom Litting ### Related Stocks - [600521.CN](https://longbridge.com/en/quote/600521.CN.md) ## Related News & Research - [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md) - [While Everyone Chases AI, Pharma Keeps Getting Cheaper](https://longbridge.com/en/news/286650835.md) - [](https://longbridge.com/en/news/286948461.md) - [Doceree launches Daily Command, an AI platform for brand teams co-built by pharma leaders](https://longbridge.com/en/news/286583833.md) - [Unlocking more value from mature drug products through strategic outsourcing](https://longbridge.com/en/news/286797687.md)